Novartis confirmed its acquisition of Anthos Therapeutics for up to $3.1 billion—securing a promising Phase III-stage anticoagulant aimed at …
Novartis confirmed its acquisition of Anthos Therapeutics for up to $3.1 billion—securing a promising Phase III-stage anticoagulant aimed at …
January’s investment activity saw a wave of biotech Series funding, with Verdiva Bio, Aviceda Therapeutics, Windward Bio, and …
Allakos faced a major setback as its chronic hives drug AK006 failed to outperform placebo in a key …
Backed by top-tier investors, the new biotech aims to redefine psychiatric care with precision neurotherapeutics
With a landmark $277 million raise, Element Biosciences is scaling its AVITI™ platform and diving deep into multi-omics—reshaping …
From schizophrenia to sleep apnoea, 2024 closes with landmark approvals that could redefine treatment standards across multiple therapeutic …
November 2024 brought promising clinical trial results, including a new CAR-T therapy showing high remission rates in relapsed …
Clinical research in 2024 is progressing rapidly, driven by pioneering studies, technological innovation, and evolving regulatory frameworks that …
Despite economic caution, pharma and biotech leaders invest boldly to reshape pipelines and accelerate innovation.
Already a subscriber? Log in